NCT06102746View on ClinicalTrials.gov

Clinical Study of Surufatinib Plus Sintilimab Combined With Chemotherapy in the Treatment of Advanced Gastric Neuroendocrine Carcinoma

RecruitingOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

April 10, 2023

Primary Completion Date

April 10, 2026

Study Completion Date

April 10, 2026

Conditions

Gastric Neuroendocrine Carcinoma

Interventions

DRUG

Sintilimab，Surufatinib

Based on the standard EP regimen, the combination of surufatinib (anti-angiogenic therapy) and sintilimab (PD-1 inhibitor) were used among patients with advanced gastric neuroendocrine carcinoma.

Trial Locations (1)

300060

RECRUITING

Tianjin Medical University Cancer Institute and Hospital, Tianjin

All Listed Sponsors

lead

Tianjin Medical University Cancer Institute and Hospital

OTHER